Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO). Celonic’s mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic.
Cellex Cell Professionals
Cellex is an end-to-end CDMO based in Cologne, Germany with 10+ years’ experience in manufacturing autologous & allogenic cell and gene therapy (CGT) products. We support customers from preclinical development stages through clinical manufacturing to commercialization. Currently, Cellex is manufacturing several final drug products (FDPs) and cellular intermediates (ITMs) including commercial products. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as GDP-compliant logistics services for cellular materials. | Cellex is a European-based end-to-end CDMO with deep expertise in the development and GMP manufacturing of autologous and allogeneic cell and gene therapy (CGT) products. With a demonstrated GMP track record of more than 20 years, Cellex supports partners from preclinical development through clinical manufacturing to commercialization, serving top 10 pharma companies, leading biotech companies, innovative start-ups, and academic centers worldwide. Cellex operates more than 26,500 sqft of GMP manufacturing facilities and holds multiple manufacturing licenses covering cellular intermediates and final drug products. The company is involved in the manufacture of three approved CAR-T therapies and has produced over 9,000 CGT/ATMP batches. Through its own apheresis center and donor database, Cellex has performed more than 50,000 cell collections for CGT and stem cell transplantation, and provides a broad portfolio of starting materials – including leukopaks, mobilized leukopaks, bone marrow, and whole blood – from both healthy donors and patients affected by specific diseases, for R&D, clinical, and commercial use. All collections are performed under GMP conditions and supplied globally. EU QP services, consulting, and GMP audits of apheresis centers worldwide complement Cellex’s offering, which is characterized by scientific expertise, quality, and flexibility.
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with experience in the development and manufacturing of cell therapies. Our leaders have played an instrumental role in shaping the cell therapy development and manufacturing methods and technologies. Our technically strong team has been recognized by our partners for their ability to manufacture and release products successfully. Cellipont is committed in helping our partners to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. Cellipont Bioservices has a team of subject-matter-experts with extensive experience in the translation of your process from benchtop to bedside. Our team has hands on experience within autologous and allogenic cell therapies, and native & genetically modified cells. We have proven in-house scientific and manufacturing expertise for all phases of clinical products for our range of clients from Pre-Clinical to Late Phase commercialization. Our extensive experience spans across multiple product areas, including: CAR-T/TCR-T DCs Fibroblasts NK MSCs HSCs TIL Cell Banking (MCB, WCB) Feeder Cell Banks Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 1,800 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont Bioservices’ growth with deep knowledge of what it takes to succeed in this space. Cellipont cell therapy scientists in lab Located in The Woodlands, Texas right outside of Houston, Cellipont Bioservices facilities and quality systems are GMP-compliant. Cellipont Bioservices is privately held. Our core investor, Great Point Partners, is a dedicated healthcare-focused investment firm with an extensive track record in successfully building biologics services businesses. | Cellipont Bioservices firmly believes that cell therapies deserve personalized and dedicated support. Our team is comprised of tenured experts within the cell therapy space, working on advancing a wide spectrum of cell modalities from CAR-T, iPSC to DCs and MSCs. Located in The Woodlands, Texas, we are strategically located near some of the best medical centers in the world. We strive to lead alongside our partners from the forefront of innovation, translating cutting-edge processes from lab to bedside. | Cellipont Bioservices is a contract development and manufacturing organization (CDMO) dedicated exclusively to advanced therapies, supporting biotech and biopharma companies developing cell therapies from preclinical stages through commercial supply. The company provides integrated development, analytical, and GMP manufacturing solutions designed to accelerate clinical timelines while maintaining regulatory readiness and product quality. The organization has commercial manufacturing experience, and its facility is designed to support both early clinical development and commercial programs. The organization specializes in autologous and allogeneic cell therapy modalities, including CAR-T, TCR-T, NK, stem cell, and other engineered immune cell products. Its services are structured to bridge the gap between early process concepts and scalable, regulatory-compliant manufacturing workflows, enabling sponsors to transition efficiently from research into clinical production and long-term commercial supply.
CatSci
Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, pre-formulation, analytical development, HPAPI development and non-GMP material supply, and recently launched their oligonucleotides capability. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. CatSci’s overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a ‘digital first, intelligent automation next’ business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers’ problems. Their purpose is and always will be to get medicines into the hands of patients in need. | CatSci Ltd is a UK-based award-winning innovation partner, dedicated to breaking down the silos in the development of small molecules, TACs and glues, and oligonucleotides to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). | CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in the CMC development of small molecules, TACS, glues, oligonucleotides and other complex medicines to accelerate the delivery of life-changing therapeutics to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees), and the 2022 Cardiff Business Award (International Business of the Year). | Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, preformulation, analytical development, HPAPI development and oligonucleotide development, they recently launched their peptide and bioscience capability.
CAREGEN
Caregen is a global biotechnology company that has commercialized the unlimited expandability of its patented peptides as many innovative products. Over 600 different functional peptides developed by Caregen for the past 21 years have opened new paradigm in the field of biotechnology by expanding its applications to cosmeceutical, Class III medical devices, food supplements, and pharmaceuticals. | Caregen, a global leader in peptide research and development, is a global biotechnology company that has commercialized its patented peptides as many innovative products since its establishment in 2001. Over 600 different functional peptides developed by Caregen for the past 24 years have opened new paradigms in the field of biotechnology by expanding its applications to cosmeceutical, Class III medical devices, food supplements, and pharmaceuticals. Our innovative peptide-based products provide total healthcare solutions to many people around the world who are pursuing health and beauty. | Caregen is a global leader in peptide R&D, headquartered in South Korea. Since 2001, Caregen has developed and commercialized over 1,500 functional peptides, driving innovation across cosmeceuticals, Class III medical devices, nutraceuticals, and pharmaceuticals. The company’s mission is to enhance life and health through the development, production, and global distribution of advanced functional peptides. Its products support wellness, metabolic balance, and healthy aging for people worldwide. Caregen’s research goes beyond biomimetic peptides. It uses proprietary peptide engineering to improve efficacy, safety, and delivery, enabling new possibilities in pharmaceutical applications.
C Ray Therapeutics (Chengdu) Co., Ltd.
C Ray Therapeutics Group operates an R&D center in Shanghai, focused on proprietary pipeline development. This covers early discovery, process development, clinical research, and registration. The company has established over 10 development pipelines targeting solid tumors, utilizing isotopes such as Cu-64, Lu-177, and Ac-225, with a variety of ligands, including small molecules, peptides, and modified antibodies. Several pipelines feature globally innovative molecules with independent intellectual property rights. | C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding. C-Ray has 28,000 square-meter, state-of-the-art, world class R&D and cGMP manufacturing facilities with the highest Class A Radiation Safety License, allowing commercial scale operational volume of over 30+ radioisotopes. GLP-like preclinical study center has both small and large lab animal use permit with animal feeding and administration lab, animal PET/CT for imaging, gama counter and pathology lab for biodistribution and dosimetry analysis. C-Ray has successfully delivered and continues to operate 70 CRDMO projects, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. Among these, 5 have entered the IND and IND-enabling stages, 16 have advanced to investigator-initiated trials (IITs), and 5 have entered the clinical supply stage, with 2 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain. As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 19 Ac-225–labeled projects.
BSP PHARMACEUTICALS S.p.A
BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds. With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing. The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine Production area includes: – a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL
BORA PHARMACEUTICAL SERVICES INC.
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing and packaging of complex oral solid dose, liquid, and semi-solid pharmaceutical Rx and OTC products for clinical and commercial uses. From cell-line development and formulation to analytical services and clinical cGMP manufacturing, Bora now provides tailored development and manufacturing services to biologics developers end-to-end. | Bora Pharmaceuticals is a premier global contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, and semi-solid pharmaceutical products for clinical and commercial uses. From cell-line development and formulation to analytical services and clinical cGMP manufacturing, Bora provides tailored development and manufacturing services to biologics developers.
Boehringer Ingelheim Biopharmaceuticals GmbH
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Boehringer Ingelheim BioXcellence™ creates solutions with its partners to reliably supply innovative therapies. One of the world’s largest manufacturers of biopharmaceuticals and an industry pioneer with in-depth experience, Boehringer Ingelheim BioXcellence™ so far has supplied more than 40 commercial products through its global network. | Boehringer Ingelheim is a leading research-driven biopharmaceutical company and creates value through innovation in areas of high unmet medical need. As one of the world’s largest manufacturers for biopharmaceuticals with in-depth experience in this field, the company is an industry pioneer and collaborates with top 20 pharma companies and innovative biotechs. Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come. We create solutions with our partners, building on our can-do attitude to improve patient health. Our business is empowered by more than 5,000 dedicated and well-trained employees in development, quality and manufacturing and has access to a global manufacturing network providing the entire production chain from DNA to Aseptic Filling. Our track records, both in commercial and clinical supply speak for themselves – since we started offering contract manufacturing in 1995, we have successfully brought 45 biologics to the market and have transferred and optimized more than 150 development and manufacturing projects at all stages from our customers to our facilities, as well as within our network. While collaborating with our partners we never lose sight of the patients that depend on biopharmaceutical therapies. We offer capabilities to complement your expertise, so together we can deliver better therapies. | As one of the world’s largest manufacturers of biopharmaceuticals, we leverage our in-depth industry experience for collaborating with top pharma and biotech companies. Our contract manufacturing business Boehringer Ingelheim BioXcellence™ is built on profound experience in key technologies – mammalian and microbial derived biopharmaceuticals – and supported by a global manufacturing network ranging from US via Europe to Asia that handles the entire production chain, from DNA to aseptic filling. Our track record in commercial and clinical supply is impressive – since initiating contract manufacturing in 1998, we’ve successfully brought 48 biologics to market. Furthermore, we transferred and optimized over 150 development and manufacturing projects focusing on late stage and commercial supply. We collaborate with partners worldwide, offering capabilities that complement their expertise. Together we turn biologic innovation into commercial success. Boehringer Ingelheim BioXcellence™ is always open to partner on contract manufacturing needs concerning your business. Contact us via www.BioXcellence.com | BioXcellence Manufacturing – Tailored Capacities. Reliable Supply. Your Success, Our Commitment. Boehringer Ingelheim BioXcellence™ is one of the leading biopharmaceutical contract manufacturers — a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation, streamlining your product’s lifecycle. We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, optimal preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals. With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharmaceutical medicines to the market. Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With around 460 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.